NeuroSearch A/S

NEUR 
(NasdaqOMXC) 
 
dkk 3.58 <%= Resources.Global.txtDown %>
Updated 15:55:00
Change % -0.28% Stock price decreasing
Change -0.01 Stock price decreasing
Volume 20,319
High DKK 3.59
Low DKK 3.54
Open DKK 3.59
ISIN DK0010224666
Prev close DKK 3.59
# of shares 24.55M
Market cap 87.90M DKK
Intraday

Market closed
NeuroSearch A/S
Market is closed, opens at 08:00
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  3.58 -0.8% Stock price decreasing 2.9% Stock price increasing -0.6% Stock price decreasing 2.3% Stock price increasing 33.6% Stock price increasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2016
0
-6,300
22,815
71,383
79,421
2015
0
-6,488
-5,538
72,400
78,594
2014
0
-13
-8
78
84
2013
29
-10
12
88
92
2012
121
-290
-276
81
208
2011
0
-383
-678
321
841
2010
69
-328
-259
994
1,392
2009
85
-356
-287
1,174
0
2008
67
-366
-382
0
0
2007
115
-253
-268
1,121
0
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Vivus Inc 1.02 0.5% Stock price increasing -18.8% Stock price decreasing -2.4% Stock price decreasing -6.9% Stock price decreasing -3.3% Stock price decreasing -11.7% Stock price decreasing
 
H Lundbeck A/S 382.90 1.8% Stock price increasing 2.3% Stock price increasing 13.9% Stock price increasing 33.1% Stock price increasing 41.6% Stock price increasing 33.3% Stock price increasing

Company profile

NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.

Peers

Instruments Last Change  
Vivus Inc 1.02 -0.5% Stock price decreasing
0,0,0,0,0,0,0,0,0,0
Lundbeck A/S 382.90 0.6% Stock price increasing
31,64,69,66,82,90,92,83,60,53

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 August 2017 16:26:43
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170808.1 - EUROWEB4 - 2017-08-17 17:26:43 - 2017-08-17 16:26:43 - 1000 - Website: OKAY